文献速递淋巴瘤

浆母细胞淋巴瘤整合基因组与转录组分析揭示关键调控通路破坏

Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
PubMed 文献 · Blood Adv · 2022-01-01

该研究对33例浆母细胞淋巴瘤(PBL)肿瘤进行全外显子组测序和转录组测序,整合分析体细胞突变与基因表达谱。研究发现JAK-STAT、RAS、NF-κB等通路频繁突变,且EBV状态影响抗原加工和细胞周期调控。EBV+与EBV- PBL存在可靶向的信号通路差异,支持PBL作为独立疾病实体。

要点

  • PBL中JAK-STAT和RAS通路基因频繁突变。
  • EBV+ PBL几乎 exclusive 上调PI3K/AKT/mTOR信号。
  • EBV- PBL中NTRK3表达显著诱导并伴反复致癌突变。

核心结论

  • PBL的突变和转录组景观不同于弥漫大B细胞淋巴瘤和多发性骨髓瘤,支持其病理生物学独立性。

研究设计与样本

  • 对33例PBL肿瘤(含HIV阳性和HIV阴性)进行全外显子组测序和RNA测序,并整合分析体细胞突变与基因表达谱。

主要发现

  • JAK信号转导及转录激活通路(OSMR、STAT3、PIM1、SOCS1)和受体酪氨酸激酶RAS通路(ERBB3、NRAS、PDGFRB、NTRK)显著累积突变。
  • NF-κB信号(NFKB2和BTK)频繁扰动。
  • RNA测序诱导通路与突变谱一致,IL-6/JAK/STAT、NF-κB和MYC信号突出。
  • I类主要组织相容性复合体介导的抗原加工和细胞周期调控显著受EBV状态影响。
  • EBV+ PBL几乎 exclusive 上调PI3K/AKT/mTOR信号;EBV- PBL中NTRK3表达显著诱导并伴反复致癌突变。

关键数值与推荐

  • 33例PBL肿瘤中JAK-STAT和RAS通路多个基因显著累积突变。
  • EBV+ PBL中PI3K/AKT/mTOR信号几乎 exclusive 上调。
  • EBV- PBL中NTRK3表达显著诱导并伴反复致癌突变。

临床怎么用

  • PBL亚组可根据EBV状态和突变通路(如PI3K/AKT/mTOR、NTRK3)探索靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasmablastic lymphoma (PBL) represents a clinically heterogeneous subtype of aggressive B-cell non-Hodgkin lymphoma. Targeted-sequencing studies and a single-center whole-exome sequencing (WES) study in HIV-positive patients recently revealed several genes associated with PBL pathogenesis; however, the global mutational landscape and transcriptional profile of PBL remain elusive. To inform on disease-associated mutational drivers, mutational patterns, and perturbed pathways in HIV-positive and HIV-negative PBL, we performed WES and transcriptome sequencing (RNA-sequencing) of 33 PBL tumors. Integrative analysis of somatic mutations and gene expression profiles was performed to acquire insights into the divergent genotype-phenotype correlation in Epstein-Barr virus-positive (EBV+) and EBV- PBL. We describe a significant accumulation of mutations in the JAK signal transducer and transcription activator (OSMR, STAT3, PIM1, and SOCS1), as well as receptor tyrosine-kinase RAS (ERBB3, NRAS, PDGFRB, and NTRK) pathways. We provide further evidence of frequent perturbances of NF-κB signaling (NFKB2 and BTK). Induced pathways, identified by RNA-sequencing, closely resemble the mutational profile regarding alterations accentuated in interleukin-6/JAK/STAT signaling, NF-κB activity, and MYC signaling. Moreover, class I major histocompatibility complex-mediated antigen processing and cell cycle regulation were significantly affected by EBV status. An almost exclusive upregulation of phosphatidylinositol 3-kinase/AKT/mTOR signaling in EBV+ PBL and a significantly induced expression of NTRK3 in concert with recurrent oncogenic mutations in EBV- PBL hint at a specific therapeutically targetable mechanism in PBL subgroups. Our characterization of a mutational and transcriptomic landscape in PBL, distinct from that of diffuse large B-cell lymphoma and multiple myeloma, substantiates the pathobiological independence of PBL in the spectrum of B-cell malignancies and thereby refines the taxonomy for aggressive lymphomas.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Witte HM, Künstner A, Hertel N, et al. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. Blood Adv. 2022. PMID: 34714908. doi:10.1182/bloodadvances.2021005486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。